Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 3/20 | 0.40 |
| ▸ | FNTB | P49356 | 3/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24127176 | 0.91 | ALPL (0.58) | ALPLMAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL21786532 | 0.84 | ALPL (0.51) | ALPLMAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL23913081 | 0.81 | GYS1 (0.41) | MAPTL3MBTL1XDHPTGER1 | |
| SCHEMBL22791325 | 0.80 | PTGDR2 (0.44) | ALPLMAPTXDHPTGER1 | |
| SCHEMBL19319832 | 0.75 | GPR55 (0.47) | MAPTRAB9AL3MBTL1FNTAFNTB | |
| SCHEMBL5937220 | 0.75 | ALPL (0.70) | ALPLMAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL21786591 | 0.75 | KMT2A (0.41) | ALPLMAPTNPC1RAB9AKMT2A | |
| SCHEMBL22791300 | 0.73 | ARF6 (0.39) | MAPTXDHALDH1A1PTGER1 | |
| SCHEMBL21786408 | 0.73 | HPGD (0.45) | MAPTNPC1RAB9AL3MBTL1TDP1 | |
| SCHEMBL21786533 | 0.72 | ALPL (0.43) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | ALPL 4695/4885MAPT 3689/4885NPC1 2687/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | ALPL 4695/4885MAPT 3689/4885NPC1 2687/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | ALPL 4695/4885MAPT 3689/4885NPC1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.